['rheumatoid arthritis']
['methotrexate']

        Inclusion Criteria:

          -  Diagnosis of RA for at least 6 months prior to screening, and American College of
             Rheumatology (ACR) functional class I-III

          -  Subjects treated with and tolerating MTX

          -  Active RA

          -  Others as defined in the protocol

        Exclusion Criteria:

          -  Have been treated with disease-modifying antirheumatic drugs (DMARDs)/systemic
             immunosuppressives other than MTX.

          -  Have received approved or investigational biological or targeted synthetic DMARD
             therapies for RA less than 6 months prior to screening.

          -  Have a history of toxicity, non-tolerance, primary non-response or inadequate response
             to a biological therapy, or targeted synthetic DMARDs, for RA.

          -  Have received prior therapy blocking the interleukin-6 (IL-6) pathway, at any time.

          -  Others as defined in the protocol
      